Abstract Body

Background

In 2020, Tanzania conducted a facility-based national surveillance of HIV drug resistance among people living with HIV (PLHIV). It was observed that 5.8% of PLHIV experiencing high viremia had integrase strand transfer inhibitors (INSTI) drug resistance mutations (DRMs). Therefore, five years later, we aimed to determine the trends and patterns of acquired drug resistance mutations (DRMs) in Tanzania using the recommended WHO laboratory-based HIV drug resistance (HIVDR) survey, utilising residual plasma.

Methods

A national cross-sectional laboratory-based HIVDR study, involving 14 out of 24 HIV viral load (HVL) testing laboratories, was conducted in Tanzania. HVL at the testing laboratories was estimated using the Cobas® 8800 System (Roche Molecular System, Inc., South Branchburg, New Jersey, USA). The PLHIV samples with high HVL ≥ 1000 copies/mL were identified and randomised to obtain a total of 220 remnant samples, which were later subjected to HIVDR genotyping. The HVL laboratory-based information management system and the CTC3/Macro database were used to obtain participants’ data. HIV genes, reverse transcriptase and protease (PRRT), and integrase (IN) were amplified by Polymerase Chain Reaction (PCR) and directly sequenced using Applied Biosystems 3500 DNA Analyser. The Stanford HIVDR database was used for HIVDR assignment. 

Results

The mean age and standard deviation (SD) for children and adults whose samples were genotyped were 9 ± 4.2 and 40 ± 13 years, respectively. The median viral load was 63,200 and IQR ( 19,060 – 210,421) copies/mL, and 90.5% of participants were on a DTG-based regimen. A high success rate of amplification was observed for the IN region, with 90.9% (200/220), and for PRRT, 82.3% (181/220). The overall prevalence of HIV DRMs was 47%. Notably, 17.4% of participants had INSTI resistance, including major DRMs: E138K, G118R, T66A, Y134K, R263K, and Q148N. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), and protease inhibitors (PIs) were detected in 37.1%, 16.4%, and 5.2% of the participants, respectively. 

Conclusions

The findings from this study have revealed that in a span of 5 years, there is more than a 2-fold increase in DTG resistance in PLHIV with high HIV viremia in Tanzania as detected from remnant plasma samples during routine care. The accelerated DTG resistance is of concern to the efficacy of the Tanzanian ART programme and other similar settings in Sub-Saharan Africa.